Company intelligence / Profile preview

Gateway Genomics

La Jolla, California, United Statessneakpeektest.com ↗

Ownership: Private
Development stage: Other

Overview

Gateway Genomics developed the SneakPeek Early Gender DNA Test, a non-invasive at-home test that determines fetal sex as early as six weeks into pregnancy with 99% accuracy. Over one million tests have been provided to expectant families. The company was acquired by Myriad Genetics in November 2022[1][2][4].

Therapeutic areas: Women's Health
Modalities: Diagnostic testDNA-based test
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Gateway Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gateway Genomics.

Explore the full profile